ADC Therapeutics (ADCT) Projected to Announce Quarterly Earnings on Tuesday

ADC Therapeutics (NYSE:ADCT) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect ADC Therapeutics to post earnings of ($0.21) per share and revenue of $18.69 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

ADC Therapeutics (NYSE:ADCT) last announced its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.11. The firm had revenue of $19.25 million for the quarter, compared to analyst estimates of $18.89 million. On average, analysts expect ADC Therapeutics to post ($0.80) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

ADC Therapeutics Trading Up 2.3%

ADCT stock traded up $0.04 during trading on Tuesday, hitting $1.57. 233,066 shares of the stock traded hands, compared to its average volume of 1,362,866. ADC Therapeutics has a one year low of $0.78 and a one year high of $4.98. The stock has a market cap of $201.08 million, a price-to-earnings ratio of -2.40 and a beta of 1.86. The company has a 50 day simple moving average of $1.31 and a 200 day simple moving average of $2.47.

Analysts Set New Price Targets

ADCT has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ADC Therapeutics in a report on Thursday, October 15th. Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Guggenheim lowered their target price on ADC Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Monday, August 17th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.00.

ADC Therapeutics Company Profile

ADC Therapeutics SA (NYSE: ADCT) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue.

The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen.